Original InvestigationComparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores: An Analysis of Mortality and Morbidity in PARADIGM-HF
Key Words
Abbreviations and Acronyms
Cited by (0)
PARADIGM-HF (NCT01035255) was funded by Novartis. All authors or their institutions have received funding from Novartis in relation to the PARADIGM-HF trial. Dr. Jhund has consulted for Novartis. Dr. Packer has consulted for Novartis, Pfizer, Sanofi, Cytokinetics, Cardiokinetix, BioControl, Janssen, Amgen, CardioMEMS, and Cardiorentis. Prof. McMurray’s employer, the University of Glasgow, was paid by Novartis for Prof. McMurray’s time spent as cochairman of the PARADIGM-HF trial and for other meetings and lectures related to the trial and LCZ696; and Prof. McMurray's travel and accommodation for some of these meetings was paid for by Novartis. Dr. Solomon has received research support from Novartis through a grant to Brigham and Women’s Hospital. Dr. Desai has consulted for Novartis, Merck, Relypsa, and St. Jude Medical. Drs. Gong, Lefkowitz, Rizkala, and Shi are employees of Novartis. Drs. Mosterd and Squire have received honoraria from Novartis for participation in educational events and advisory boards. Dr. Swedberg has received honoraria from Novartis for sponsored lectures. Dr. Zile is a consultant to Novartis, serving on executive and steering committees. Dr. Martinez is on the speakers bureau of Novartis; and has received research grants from Novartis and Cardiorentis. Drs. Mosterd and Squire received honoraria from Novartis for participating in various activities.